ObjectiveTo evaluate the clinical efficacy and safety of Huaban Jiedu Formulation （化斑解毒方， HJF） in treating psoriasis vulgaris with blood-heat syndrome. MethodsA randomized， double-blind， placebo-controlled study was conducted with 60 patients diagnosed with psoriasis vulgaris of blood-heat syndrome. Patients were randomly assigned to either a treatment group or a control group， with 30 cases in each. The treatment group received HJF granules orally， one dose a day， combined with topical Qingshi Zhiyang Ointment （青石止痒软膏）， while the control group received placebo granules， one dose a day， combined with the same topical ointment. Both groups were topically treated twice daily of 28 days treatment cours. Psoriasis area and severity index （PASI）， visual analogue scale for pruritus （VAS）， traditional Chinese medicine （TCM） syndrome scores， dermatology life quality index （DLQI）， and psoriasis life stress inventory （PLSI） were assessed before treatment and on day 14 and day 28. Response rates for PASI 50 （≥50% reduction） and PASI 75 （≥75% reduction）， as well as overall clinical efficacy， were compared between groups. Serum levels of interleukin-6 （IL-6） and interleukin-17 （IL-17） were measured before and after 28 days of treatment. Adverse reactions during treatment were recorded. ResultsAfter 28 days of treatment， both groups showed significant reductions in PASI total score， lesion area score， erythema， scaling， and infiltration scores， pruritus VAS score， TCM syndrome score， DLQI， PLSI， and serum IL-6 and IL-17 levels （P＜0.05）. Compared to the control group， the treatment group had significantly greater improvements in PASI total score and erythema score， TCM syndrome score， serum IL-6 and IL-17 levels， and PASI 50 response rate after 28 days （P＜0.05）. Between-group comparisons of score differences before and after 28-day treatment revealed that the treatment group showed significantly better improvements in PASI total， lesion area score， erythema score， TCM syndrome score， DLQI， PLSI， and inflammatory markers （P＜0.05 or P＜0.01）. The total effective rate on day 14 and day 28 was 40.00% （12/30） and 83.33% （25/30） in the treatment group， versus 6.90% （2/29） and 41.38% （12/29） in the control group， respectively. The clinical efficacy in the treatment group was significantly superior to that in the control group （P＜0.05）. Mild gastric discomfort occurred in 3 patients in the treatment group and 1 in the control group. ConclusionHJF can effectively improve skin lesions and TCM symptoms relieve pruritus， enhance quality of life， and reduce inflammatory markers IL-6 and IL-17， in patients with blood-heat syndrome of psoriasis vulgaris， with a good safety profile.

Objective To investigate predictive value of serum levels of long noncoding RNA differentiation antagonizes non-protein coding RNA(LncRNA DANCR)and microRNA(miR)-33a-5p in patients with gestational diabetes mellitus(GDM)on pregnancy outcome.Methods A total of 154 GDM patients who underwent prenatal examination and delivery in the Fourth People's Hospital of Hengshui from August 2021 to February 2023 were collected as the GDM group,and these patients were grouped into a good outcome group of 115 cases and an adverse outcome group of 39 cases based on pregnancy outcomes.Meantime,149 healthy pregnant women with normal glucose tolerance test for 24 weeks were collected as the control group.Realtime fluorescence quantitative PCR(qRT-PCR)method was applied to detect serum LncRNA DANCR and miR-33a-5p levels,and receiver operating characteristic(ROC)curve was used to analyze the value of serum LncRNA DANCR and miR-33a-5p in predicting adverse pregnancy outcomes in GDM patients.Pearson correlation was applied to analyze the correlation among serum LncRNA DANCR,miR-33a-5p,fasting bloodglucos(FBG),fasting insulin(FINS),and homeostasis model assessment of insulin resistance(HOMA-IR)in patients with GDM adverse pregnancy outcomes.Logistic regression was used to analyze the influencing factors of adverse pregnancy outcomes in GDM patients.Results The serum LncRNA DANCR level(0.69±0.15)in the GDM group was lower than that in the control group(1.01±0.22),while the level of miR-33a-5p(1.59±0.40)and the total incidence of adverse pregnancy outcomes(25.34％)were higher than those in the control group(1.02±0.23,5.36％),with significant differences(t/x2=14.835,15.140,23.011,all P＜0.05).The serum LncRNADANCR level(0.50±0.14)in the adverse outcome group was lower than that in the good outcome group(0.75±0.18),while miR-33a-5p(2.00±0.58),FBG(8.97±0.66mmol/L),FINS(18.63±1.31pmol/ml)and HOMA-IR(7.42±0.98)were higher than those in the good outcome group(1.45±0.26,8.01±0.59mmol/L,14.32±1.29pmol/ml,5.10±0.86),the differences were statistically significant(t=7.895～17.961,all P＜0.05).The areas under curve(AUC)of predicting adverse pregnancy outcomes in GDM patients with LncRNA DANCR and miR-33a-5p alone and in combination were 0.820,0.819 and 0.897,respectively.For patients with GDM adverse pregnancy outcomes,serum LncRNA DANCR was negatively correlated with FBG,FINS and HOMAIR(r=-0.498,-0.513,-0.509,allP＜0.05),while miR-33a-5p was positively correlated with FBG,FINS and HOMA-IR(r=0.517,0.494,0.507,all P＜0.05).LncRNA DANCR was a protective factor that affected adverse pregnancy outcomes in GDM patients(OR=0.804,95％CI:0.693～0.933,P=0.004);while miR-33a-5p was a risk factor for adverse pregnancy outcomes in GDM patients(OR=2.747,95％CI:1.444～5.225,P=0.002).Conclusion LncRNA DANCR was decreased and miR-33a-5p was increased in GDM patients with adverse pregnancy outcomes,indicating both may be influencing factors for adverse pregnancy outcomes.